Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OQR300
- Development stage
- Preclinical
- Lead developer
- OncoQr
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
OQR300 is a preclinical-stage therapeutic cancer vaccine being developed by the Austrian biotechnology company OncoQR ML GmbH. The drug is built upon the proprietary S-TIR™ (Specific Total Immune Remodeler) platform, which is designed to induce high-titer, specific antibody responses against clinically validated targets by bypassing immune tolerance. The S-TIR™ technology utilizes a modular design consisting of a generic 'warhead' module to activate the immune system and a disease-specific 'immunogen' module. While OncoQR describes the target of OQR300 as a '3rd blockbuster-clinically validated target,' the specific molecular target and the primary cancer indication have not been publicly disclosed.
02
Targets
BCR (Immunoglobulin G B Cell Receptor)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)FCGR2B (Fc gamma receptor IIB)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on OQR300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OQR300.